-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Rl+PeIf4alqh6ZFKi3Oxynh1/l1IkSdLsr5avwDXFADWSvchlFSg2pibUCYKj18P
 FSIx5dI8hzab4ONwzTB5pA==

<SEC-DOCUMENT>0000917520-04-000036.txt : 20041216
<SEC-HEADER>0000917520-04-000036.hdr.sgml : 20041216
<ACCEPTANCE-DATETIME>20041216083544
ACCESSION NUMBER:		0000917520-04-000036
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20041214
FILED AS OF DATE:		20041216
DATE AS OF CHANGE:		20041216

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INTEGRA LIFESCIENCES HOLDINGS CORP
		CENTRAL INDEX KEY:			0000917520
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				510317849
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		311 C ENTERPRISE DRIVE
		CITY:			PLAINSBORO
		STATE:			NJ
		ZIP:			08536
		BUSINESS PHONE:		6092750500

	MAIL ADDRESS:	
		STREET 1:		311 C ENTERPRISE DRIVE
		CITY:			PLAINSBORO
		STATE:			NJ
		ZIP:			08536

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTEGRA LIFESCIENCES CORP
		DATE OF NAME CHANGE:	19950614

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			ESSIG STUART
		CENTRAL INDEX KEY:			0001187574

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26224
		FILM NUMBER:		041206385

	MAIL ADDRESS:	
		STREET 1:		311 C ENTERPRISE DRIVE
		CITY:			PLAINSBORO
		STATE:			NJ
		ZIP:			08536
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>seform4121504_ex.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0202</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2004-12-14</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0000917520</issuerCik>
        <issuerName>INTEGRA LIFESCIENCES HOLDINGS CORP</issuerName>
        <issuerTradingSymbol>IART</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001187574</rptOwnerCik>
            <rptOwnerName>ESSIG STUART</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>311 C ENTERPRISE DRIVE</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>PLAINSBORO</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>08536</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>President and CEO</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Variable Forward Sale Contract</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F1"/>
                <footnoteId id="F2"/>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2004-12-14</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>J</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
                <footnoteId id="F2"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>1</value>
                    <footnoteId id="F1"/>
                    <footnoteId id="F2"/>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F1"/>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <value>2013-03-28</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>500000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>1</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">On December 14, 2004, Stuart M. Essig, the President and Chief Executive Officer of Integra LifeSciences Holdings Corporation
(the &quot;Company&quot;), entered into a variable forward sale contract (the &quot;Forward Sale Contract&quot;) with Credit Suisse First Boston
Capital LLC (&quot;CSFB&quot;) for 500,000 shares of the Company's common stock. Pursuant to the terms of the Forward Sale Contract,
CSFB will sell up to 500,000 shares of the Company's common stock into the public market in accordance with paragraphs (f)
and (g) of Rule 144 under the Securities Act of 1933, as amended.</footnote>
        <footnote id="F2">The terms of the Forward Sale Contract provide that on March 28, 2013 (the &quot;Settlement Date&quot;), Mr. Essig will deliver
between 264,550 and 500,000 shares of the Company's common stock (or, at the election of Mr. Essig, the cash equivalent of
such shares) to CSFB. The number of shares (or the cash equivalent of such shares) that Mr. Essig will be required to
deliver to CSFB will depend upon the average price of the Company's common stock for the 20 trading days prior to and
including the Settlement Date.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Stuart M. Essig</signatureName>
        <signatureDate>2004-12-16</signatureDate>
    </ownerSignature>
</ownershipDocument>

</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----